Feature | November 24, 2014

Long-term Anti-clotting/antiplatelet Drug Combo in AFib Patients May Raise Risk of Dementia

Researchers found that atrial fibrillation patients taking warfarin were more likely to develop dementia if lab measurements of their clotting time were frequently too or too fast

AHA, warfarin, antiplatelet therapy, atrial fibrillation, anti-clotting, EP lab

Photo courtesy of American Stroke Association


November 16, 2014 — Long-term overtreatment with the anti-clotting drug warfarin, combined with antiplatelet therapy of aspirin or clopidigrel to prevent stroke, may raise the risk of dementia in people with atrial fibrillation, according to research presented at the American Heart Association’s Scientific Sessions 2014.

Researchers studied 1,031 patients with no previous history of stroke or dementia for up to 10 years while on the drug combination. After adjusting for traditional stroke and bleeding risk factors, patients who had abnormally slow blood clotting times — International Normalized Ratio (INR) measurement above 3 — on 25 percent or more of their monitoring tests were more than twice as likely to be diagnosed with dementia than patients whose tests showed overtreatment less than 10 percent of the time. The increase is higher than what researchers found in a previous study of warfarin alone.

Patients who had abnormally slow clotting times were considered to be receiving too much medication.

Researchers previously found that atrial fibrillation patients taking warfarin were more likely to develop dementia if lab measurements of their clotting time were frequently too slow or too fast. From those results they concluded that brain injury from both small bleeds and clots was important in the development of dementia in atrial fibrillation patients.

If you’re taking warfarin and an antiplatelet drug such as aspirin or clopidgrel, check with your doctor to make sure you need one or both of the long-term antiplatelet medications, Bunch said.

Most patients in the study were Caucasian; researchers aren’t sure results would apply to other ethnic groups.

For more information: www.heart.org


Related Content

News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
News | Cardiovascular Clinical Studies

May 17, 2024 — Royal Philips, a global leader in health technology, is presenting new retrospective study results ...

Home May 17, 2024
Home
News | Cardiovascular Clinical Studies

May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the ...

Home May 15, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Even though mortality and hospitalization rates have improved, the quality of life for those living with ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 10, 2024 — Scientists from Immanuel Kant Baltic Federal University proved that Raman spectroscopy, a method by which ...

Home May 10, 2024
Home
Subscribe Now